Press Releases
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jul 29, 2013Digital PCR system adoption helps create ultra-sensitive cell-free DNA assay
-
Jul 24, 2013Patent covers methods of detecting cell-free microRNA in urine and blood
-
Jul 22, 2013Trovagene develops ultra-sensitive cell-free DNA assay
-
Jun 27, 2013Presentation scheduled on June 27, 2013 at 9:20 a.m. ET in New York
-
Jun 3, 2013Presentation scheduled on June 6, 2013 at 3:00 p.m. ET in New York
-
Mar 27, 2013New, non-invasive molecular diagnostic test is easy, fast, and accurate
-
Mar 12, 2013Presentation scheduled on March 19, 2013 at 12:00 p.m. PT at the Ritz-Carlton Laguna Nigel, in Dana Point, CA
-
Feb 5, 2013Presentation scheduled on February 13, 2013 at 9:00 a.m. ET at the Waldorf Astoria in New York City
-
Jan 2, 2013Study with MD Anderson will compare detection of BRAF mutations in urine to biopsy samples, and monitor therapeutic response, outcomes
-
Nov 18, 2012Renowned molecular geneticist strengthens Trovagene's scientific expertise
-
Nov 14, 2012COMPANY CONTINUES TO DEVELOP PROGRAMS IN CANCER AND INFECTIOUS DISEASE DETECTION IN URINE
-
Aug 28, 2012Issuance of First US NPM1 Patent Triggers Milestone Payment
-
Aug 14, 2012COMPANY CONTINUES TO EXPAND PROGRAMS IN CANCER AND INFECTIOUS DISEASE DETECTION IN URINE
-
Jul 2, 2012Study will compare detection of KRAS mutations in urine to their detection in biopsy samples
-
Jun 24, 2012
-
Apr 30, 2012Internationally recognized cancer researcher and physician strengthens Trovagene's scientific expertise in cancer genetics
-
Apr 30, 2012Trovagene Announces Validation Program for Trans-Renal K-RAS Mutation Detection in Pancreatic CancerCompany plans to establish comprehensive panel of assays to detect oncogene mutations in the urine of cancer patients
-
Apr 22, 2012- Pharmaceutical and diagnostic sales and marketing executive will provide leadership to accelerate commercial programs -
-
Jan 5, 2012
-
Jan 2, 2012License Complements Franchise of the Company's Proprietary Tumor Marker Assets in Hematological Cancers